Announced
Financials
Tags
Majority
Pharmaceuticals
precision medicine
Merger
Friendly
Private
Pending
United States
molecular diagnostics
Single Bidder
Synopsis
OpGen, a precision medicine manufacturer to merge business with Curetis, a developer of molecular diagnostic solutions. Financial terms were not disclosed. "We are convinced that the combination of OpGen and Curetis will help maximize value for our stockholders and will result in an organization with a robust pipeline of molecular diagnostic and bioinformatics products, significant management experience, and proprietary assets for developing and commercializing novel data-driven solutions in infectious disease diagnostics,” Evan Jones, OpGen Chairman and CEO. Curetis shareholders have voted to approve the merger.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.